Study Details
Testing the Drug mRNA-1345 to Protect Infants from RSV
(IRB#: IRB_00169145)
RSV is a virus that infects the lungs and respiratory tract - the parts of the body related to breathing. It can cause a runny nose, sore throat, cough, and fever. RSV can lead to serious respiratory tract problems like pneumonia and bronchiolitis. Infants under 6 months of age are at the greatest risk of having severe RSV. This study will test whether vaccinating pregnant women with a study drug called mRNA-1345 helps prevent RSV disease in their babies. People who are pregnant in the study will be randomly chosen to be treated with mRNA-1345 or a placebo. A placebo looks like the study drug but does not have the active drug. Participation in the study lasts about 15 months. Medical tests will be done during the study to track the health of participants.
- Female Only
- Under 7 or over 18 years old
- Healthy Volunteers
- In Person
- Paid
Who can participate?
Gender: Female Only
Age: Under 7 or over 18 years old
Volunteers: Healthy Volunteers
Location: In Person
Inclusion Criteria
- Ages 18 to 40 years old
- Healthy and pregnant between 24 and 36 weeks
- Expecting to deliver the baby at the University of Utah
Will I be paid for my time?
Yes
IRB#: IRB_00169145
PI: Torri Metz
Department: MATERNAL-FETAL MEDICINE DIV
Approval Date: 2024-07-03 06:00:00
Specialties: OB/Gyn, General
I am Interested